[1]
|
Palumbo, A. and Anderson, K. (2011) Multiple Myeloma. The New England Journal of Medicine, 364, 1046-1060.
https://doi.org/10.1056/NEJMra1011442
|
[2]
|
Brigle, K. and Rogers, B. (2017) Pathobiology and Diagnosis of Multiple Myeloma. Seminars in Oncology Nursing, 33, 225-236. https://doi.org/10.1016/j.soncn.2017.05.012
|
[3]
|
Terhorst, C., et al. (1981) Biochemical Studies of the Human Thymocyte Cell-Surface Antigens T6, T9 and T10. Cell, 23, 771-780. https://doi.org/10.1016/0092-8674(81)90441-4
|
[4]
|
Reinherz, E.L., et al. (1980) Discrete Stages of Human In-trathymic Differentiation: Analysis of Normal Thymocytes and Leukemic Lymphoblasts of T-Cell Lineage. Proceedings of the National Academy of Sciences of the United States of America, 77, 1588-1592. https://doi.org/10.1073/pnas.77.3.1588
|
[5]
|
Malavasi, F., et al. (1994) Human CD38: A Glycoprotein in Search of a Function. Immunology Today, 15, 95-97.
https://doi.org/10.1016/0167-5699(94)90148-1
|
[6]
|
Deaglio, S., et al. (2007) CD38 and ZAP-70 Are Functionally Linked and Mark CLL Cells with High Migratory Potential. Blood, 110, 4012-4021. https://doi.org/10.1182/blood-2007-06-094029
|
[7]
|
Malavasi, F., et al. (2011) CD38 and Chronic Lymphocytic Leukemia: A Decade Later. Blood, 118, 3470-3478.
https://doi.org/10.1182/blood-2011-06-275610
|
[8]
|
Sanchez, L., et al. (2016) Daratumumab: A First-in-Class CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma. Journal of Hematology & Oncology, 9, Article No. 51. https://doi.org/10.1186/s13045-016-0283-0
|
[9]
|
Marlein, C.R., et al. (2019) CD38-Driven Mitochondrial Traf-ficking Promotes Bioenergetic Plasticity in Multiple Myeloma. Cancer Research, 79, 2285-2297. https://doi.org/10.1158/0008-5472.CAN-18-0773
|
[10]
|
Ghose, J., et al. (2018) Daratumumab Induces CD38 Inter-nalization and Impairs Myeloma Cell Adhesion. Oncoimmunology, 7, e1486948. https://doi.org/10.1080/2162402X.2018.1486948
|
[11]
|
Zhu, C., et al. (2020) Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Frontiers in Immunology, 11, Article No. 1771. https://doi.org/10.3389/fimmu.2020.01771
|
[12]
|
Viola, D., et al. (2021) Daratumumab Induces Mecha-nisms of Immune Activation through CD38+ NK Cell Targeting. Leukemia, 35, 189-200. https://doi.org/10.1038/s41375-020-0810-4
|
[13]
|
Moreau, P., et al. (2016) VTD Is Superior to VCD Prior to Inten-sive Therapy in Multiple Myeloma: Results of the Prospective IFM2013-04 Trial. Blood, 127, 2569-2574. https://doi.org/10.1182/blood-2016-01-693580
|
[14]
|
Moreau, P., et al. (2019) Bortezomib, Thalidomide, and Dex-amethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study. The Lancet, 394, 29-38. https://doi.org/10.1016/S0140-6736(19)31240-1
|
[15]
|
Voorhees, P.M., et al. (2020) Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial. Blood, 136, 936-945.
https://doi.org/10.1182/blood.2020005288
|
[16]
|
Abdallah, N. and Kumar, S.K. (2019) Daratumumab in Untreated Newly Diagnosed Multiple Myeloma. Therapeutic Advances in Hematology, 10. https://doi.org/10.1177/2040620719894871
|
[17]
|
Yimer, H., Melear, J., Faber, E., et al. (2018) Lyra: A Phase 2 Study of Daratumumab (Dara) plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood, 132, Article No. 152. https://doi.org/10.1182/blood-2018-152
|
[18]
|
Voorhees, P.M., et al. (2021) Daratumumab plus RVd for Newly Diagnosed Multiple Myeloma: Final Analysis of the Safety Run-In Cohort of GRIFFIN. Blood Advances, 5, 1092-1096. https://doi.org/10.1182/bloodadvances.2020003642
|
[19]
|
Roussel, M., et al. (2020) Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab for Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma (CASSIOPEIA): Health-Related Quality of Life Outcomes of a Randomised, Open-Label, Phase 3 Trial. The Lancet Haematology, 7, e874-e883.
https://doi.org/10.1016/S2352-3026(20)30356-2
|
[20]
|
Moreau, P., et al. (2021) Maintenance with Daratumumab or Observation Following Treatment with Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab and Autologous Stem-Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma (CASSIOPEIA): An Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 22, 1378-1390. https://doi.org/10.1016/S1470-2045(21)00428-9
|
[21]
|
Sonneveld, P. and Broijl, A. (2016) Treatment of Relapsed and Refractory Multiple Myeloma. Haematologica, 101, 396-406. https://doi.org/10.3324/haematol.2015.129189
|
[22]
|
Attal, M., et al. (2019) Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low- Dose Dexamethasone in Patients with Relapsed and Refrac-tory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 394, 2096-2107. https://doi.org/10.1016/S0140-6736(19)32556-5
|
[23]
|
Lu, J., et al. (2021) Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clinical Lymphoma, Myeloma and Leukemia, 21, e699-e709. https://doi.org/10.1016/j.clml.2021.04.012
|
[24]
|
Lonial, S., et al. (2016) Daratumumab Monotherapy in Patients with Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial. The Lancet, 387, 1551-1560.
https://doi.org/10.1016/S0140-6736(15)01120-4
|
[25]
|
Nooka, A.K., et al. (2019) Clinical Efficacy of Daratumumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Myeloma: Utility of Re-Treatment with Daratumumab among Refractory Patients. Cancer, 125, 2991-3000. https://doi.org/10.1002/cncr.32178
|
[26]
|
Nooka, A.K., et al. (2019) Daratumumab in Multiple Myeloma. Cancer, 125, 2364-2382.
https://doi.org/10.1002/cncr.32065
|
[27]
|
Dimopoulos, M.A., et al. (2016) Daratumumab, Lenalidomide, and Dexa-methasone for Multiple Myeloma. The New England Journal of Medicine, 375, 1319-1331. https://doi.org/10.1056/NEJMoa1607751
|
[28]
|
Palumbo, A., et al. (2016) Daratumumab, Bortezomib, and Dexa-methasone for Multiple Myeloma. The New England Journal of Medicine, 375, 754-766. https://doi.org/10.1056/NEJMoa1606038
|
[29]
|
Dimopoulos, M., et al. (2020) Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 396, 186-197. https://doi.org/10.1016/S0140-6736(20)30734-0
|
[30]
|
Cho, S.F., Anderson, K.C. and Tai, Y.T. (2018) Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in Immunology, 9, Article No. 1821.
https://doi.org/10.3389/fimmu.2018.01821
|
[31]
|
Zannetti, B.A., et al. (2020) Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. Cells, 9, Article No. 2666. https://doi.org/10.3390/cells9122666
|
[32]
|
Ejaz, K., et al. (2021) Daratumumab: Beyond Multiple Myeloma. Transfusion Medicine Reviews, 35, 36-43.
https://doi.org/10.1016/j.tmrv.2021.06.002
|